Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Currently, Madrigal Pharmaceuticals', Rezdiffra is the only U.S.-approved drug for MASH. Drugmakers such as Novo Nordisk and Eli Lilly are also conducting trials with their blockbuster GLP-1 ...

Other GLP-1-targeting drugs for obesity and diabetes are also being explored for their potential in MASH – including Novo Nordisk’s Ozempic/Wegovy (semaglutide) and Eli Lilly’s Mounjaro ...

The 2nd GLP-1-Based Therapeutics Summit returns to tackle the challenges in best-in-class GLP-1 development and indication ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

“Bonjour Tristesse” is writer/director Durga Chew-Bose’s directorial debut; the film premiered at 2024 TIFF.